|
Typhoid conjugate vaccine candidate aims to increase global supply
A Phase 3 study of a new typhoid conjugate vaccine (TCV) candidate called EuTCV began enrollment in Sandiara, Senegal, in early May after site initiation on April 29, 2022. PATH is working with the Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation, Senegal, and vaccine manufacturer EuBiologics to assess the safety and immune response of EuTCV in adults and young children older than six months of age. In the coming months, the trial will be expanded to a second site in Kericho, Kenya, in partnership with the Kenya Medical Research Institute-Kericho and Walter Reed Army Institute for Research. The multicenter trial will last two years.
EuBiologics will concurrently seek to have EuTCV prequalified by the World Health Organization (WHO) so that it may be acquired for subsidized use in low-income countries. The results from this study will help meet post-prequalification data requirements that would enable EuTCV to join the list of TCVs that are already globally available. The development and approval of additional TCV products has the potential to increase supply, reduce costs, and improve availability of these lifesaving vaccines. PATH also supports country TCV decision-making and introduction as a core member of the Typhoid Vaccine Acceleration Consortium.
Register and submit an abstract for VASE 2022!
Registration is now open for PATH’s third international Vaccines Against Shigella and enterotoxigenic Escherichia coli (VASE) Conference, which will be held November 29 to December 1, 2022 in Washington, DC. This year’s conference will encompass three full days and is being planned as a fully in-person event. VASE 2022 will also have an expanded scope that includes other emerging pathogens, such as Campylobacter and non-typhoidal Salmonella, as important contributors to the global diarrheal disease burden.
Researchers working in these areas are encouraged to submit their work to be considered for presentation at VASE. While the deadline for regular abstract submissions is today, June 7, 2022, late-breaking abstract submissions will also be accepted. In addition, PATH is offering a limited number of travel grants to people who need financial assistance to attend VASE 2022. Late-breaking abstracts and travel grant applications must be submitted by August 9, 2022. 
New online library supports maternal immunization for COVID-19 and beyond
The COVID-19 pandemic has triggered increased public health attention on advancing vaccination in pregnancy and a need for easily accessible key information as the landscape rapidly changes. To address this need, PATH is hosting the COVID-19 Maternal Immunization Resource Library developed in collaboration with WHO. This one-stop hub connects decision-makers, implementers, advocates, and others to the latest public health information related to COVID-19 vaccines, pregnancy, and breastfeeding.
COVID-19 increases the risk of health complications in pregnancy such as severe illness for pregnant individuals and adverse birth outcomes for newborns. Maternal immunization is a powerful public health tool—however vaccination in pregnancy is not used to its full potential as an essential health service, nor against COVID-19 (despite WHO’s interim recommendations that it should be). Updated quarterly, the new library will be an asset for stakeholders planning and advancing maternal immunization strategies for the current COVID-19 pandemic as well as for broader, cross-pathogen disease prevention.
|
